Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions
June 10, 2017 13:00 ET
|
Zafgen, Inc.
-Successful Phase 1 Clinical Trial Garners Late-Breaking ADA Presentation and Supports Advancement to Phase 2 Development- -ZGN-1061 Treatment Improves Glycemic Control and Body Weight in Preclinical...
Zafgen Reports First Quarter 2017 Financial Results
May 09, 2017 16:05 ET
|
Zafgen, Inc.
-ZGN-1061 Phase 1 Data Support Continued Development; On Track to Initiate Phase 2 Clinical Trial in Patients with Type 2 Diabetes in Second Half of This Year- BOSTON, May 09, 2017 (GLOBE NEWSWIRE)...